Anthropic has launched Claude Science, an AI platform designed to expedite the discovery of promising new therapies. The company will also use the tool internally to pursue innovative treatments for so-called neglected diseases.
The announcement focuses on the platform's potential to streamline drug development, though specific funding amounts, valuation, or investment round details were not disclosed. The tool is positioned as a specialized application of Anthropic's Claude AI models.
This move places Anthropic in the competitive AI-powered drug discovery space, where companies like Insilico Medicine and Recursion Pharmaceuticals have already made strides. The pharmaceutical industry's growing embrace of AI underscores the massive market opportunity, as traditional drug development remains costly and time-consuming.
By applying its own AI to neglected diseases—conditions often overlooked due to limited commercial incentives—Anthropic signals a willingness to tackle challenging, high-impact problems. This could pressure other AI firms to address underserved areas or risk being seen as prioritizing profit over public health.
Founders Dario and Daniela Amodei have previously emphasized Anthropic's commitment to responsible AI development. The internal use of Claude Science for neglected diseases aligns with that mission, potentially setting a precedent for how AI companies balance business goals with societal contributions.